These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33461918)

  • 41. COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.
    Fabricius MM; Dandachi D
    Mo Med; 2021; 118(1):74-80. PubMed ID: 33551490
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19).
    Gupta P
    Indian J Tuberc; 2021 Jan; 68(1):92-98. PubMed ID: 33641858
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
    Pavia CS; Wormser GP
    Int J Antimicrob Agents; 2021 Mar; 57(3):106275. PubMed ID: 33400975
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19.
    Kumar P; Sah AK; Tripathi G; Kashyap A; Tripathi A; Rao R; Mishra PC; Mallick K; Husain A; Kashyap MK
    Mol Cell Biochem; 2021 Feb; 476(2):553-574. PubMed ID: 33029696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.
    Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S
    Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925
    [No Abstract]   [Full Text] [Related]  

  • 47. [Is convalescent plasma an alternative treatment for Covid-19 patients?].
    Trejo-Gómor JE; Dimas-González J; Lagunas-Martínez A
    Salud Publica Mex; 2020; 62(6):870-871. PubMed ID: 33620985
    [No Abstract]   [Full Text] [Related]  

  • 48. An overview of Covid-19 pandemic: immunology and pharmacology.
    Arif A; Ansari S; Ahsan H; Mahmood R; Khan FH
    J Immunoassay Immunochem; 2021 Sep; 42(5):493-512. PubMed ID: 33788668
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Motivators of and barriers to becoming a COVID-19 convalescent plasma donor: A survey study.
    Masser BM; Ferguson E; Thorpe R; Lawrence C; Davison TE; Hoad V; Gosbell IB
    Transfus Med; 2021 Jun; 31(3):176-185. PubMed ID: 33368777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Convalescent Plasma in the Management of COVID-19.
    Dandachi D; Khalaf SA
    Mo Med; 2021; 118(2):118. PubMed ID: 33840851
    [No Abstract]   [Full Text] [Related]  

  • 51. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma procurement and plasma product safety in light of the COVID-19 pandemic from the perspective of the plasma industry.
    Turecek PL; Hibbett D; Kreil TR
    Vox Sang; 2022 Jun; 117(6):780-788. PubMed ID: 35298841
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.
    Kroemer M; Boullerot L; Ramseyer M; Spehner L; Barisien C; Gravelin E; Renaudin A; Cognasse F; Gallian P; Hermine O; Lacombe K; Tiberghien P; Adotévi O
    Front Public Health; 2022; 10():816848. PubMed ID: 35372242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Convalescent plasma for COVID-19 considerations.
    Adiwinata Pawitan J
    Transfus Apher Sci; 2021 Feb; 60(1):102927. PubMed ID: 32878733
    [No Abstract]   [Full Text] [Related]  

  • 55. Covid-19 convalescent plasma and SARS-CoV-2 viral variants.
    Joob B; Wiwanitkit V
    Transfus Clin Biol; 2021 Aug; 28(3):306. PubMed ID: 34116915
    [No Abstract]   [Full Text] [Related]  

  • 56. Severe COVID-19 is a T cell immune dysregulatory disorder triggered by SARS-CoV-2.
    Ameratunga R; Woon ST; Steele R; Lehnert K; Leung E; Brooks AES
    Expert Rev Clin Immunol; 2022 Jun; 18(6):557-565. PubMed ID: 35510369
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Convalescent plasma to treat COVID-19: clinical experience and efficacy.
    Pei S; Yuan X; Zhang Z; Yao R; Xie Y; Shen M; Li B; Chen X; Yin M
    Aging (Albany NY); 2021 Mar; 13(6):7758-7766. PubMed ID: 33735836
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma therapy: a passive resistance against the deadliest.
    Hansda A; Biswas D; Bhatta A; Chakravorty N; Mukherjee G
    Hum Vaccin Immunother; 2022 Apr; 18(2):2006026. PubMed ID: 34886756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19 convalescent plasma from Norwegian blood donors.
    Nissen-Meyer LSH; Hervig T; Fevang B; Norheim G; Kran AB; Vaage JT; Flesland Ø
    Tidsskr Nor Laegeforen; 2022 Jun; 142(9):. PubMed ID: 35699539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.
    Liu STH; Lin HM; Baine I; Wajnberg A; Gumprecht JP; Rahman F; Rodriguez D; Tandon P; Bassily-Marcus A; Bander J; Sanky C; Dupper A; Zheng A; Nguyen FT; Amanat F; Stadlbauer D; Altman DR; Chen BK; Krammer F; Mendu DR; Firpo-Betancourt A; Levin MA; Bagiella E; Casadevall A; Cordon-Cardo C; Jhang JS; Arinsburg SA; Reich DL; Aberg JA; Bouvier NM
    Nat Med; 2020 Nov; 26(11):1708-1713. PubMed ID: 32934372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.